uploads///Chart  BMY

How Bristol-Myers Squibb Stock Performed in 1Q17


Apr. 7 2017, Updated 3:05 p.m. ET

A look at Bristol-Myers Squibb Co.

Bristol-Myers Squibb (BMY) is an American pharmaceutical company that deals with innovative medicines for patients with serious diseases in therapeutic areas including virology, oncology, cardiovascular, neuroscience, and immuno-science.

Article continues below advertisement

Stock price performance

Bristol-Myers Squibb’s stock price fell ~11.7% in 1Q17. On April 6, 2017, the stock’s price had risen 9.2% year-to-date (or YTD).

Analysts’ recommendations

Analysts estimate that the stock has the potential to return ~4.4% over the next 12 months. Analysts’ recommendations show a 12-month target price of $55.41 per share, compared to the stock’s price of $53.08 per share on April 5, 2017.

There are 23 analysts tracking Bristol-Myers Squibb stock, and 43.5% of them recommend “buys,” 47.8% recommend “holds,” and 8.7% recommend “sells.” The consensus rating for Bristol-Myers Squibb is 2.4, representing a moderate “buy” for value investors and long-term growth investors.

Analysts’ revenue estimates

Bristol-Myers Squibb’s revenue has risen over the past few years following the strong performances of some of its key products such as Opdivo, Yervoy, Sprycel, and Empliciti in its oncology franchise, Orencia in its immuno-science franchise, and Eliquis in its cardiovascular franchise.

Analysts’ estimates show revenue of $4.7 billion, an 8% rise over 2016, and earnings per share (or EPS) of $0.75 for the company in 1Q17.

To divest company-specific risk, investors can consider ETFs such as the iShares U.S. Healthcare ETF (IYH), which holds 3.0% of its total assets in Bristol-Myers Squibb, 3.4% in AbbVie (ABBV), 10.8% in Johnson & Johnson (JNJ), and 3.2% in Allergan (AGN).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.